Advance Nanotech Subsidiary Announces Patent for New Implantable and Body-Worn Biosensors; New Technology to Improve Treatment for a Wide Range of Chronic Conditions.

NEW YORK CITY -- Bio-Nano Sensium Technologies, a subsidiary of Advance Nanotech, Inc., (OTC BB:AVNA.OB), today announced a significant step forward for wireless biosensors. Wireless biosensors are increasingly seen as a desirable treatment for a range of chronic conditions including diabetes, cardiac conditions and asthma.

Bio-Nano Sensium Technologies has filed for a patent on a new technology that will automatically bring imbedded biosensors into conformance with international frequency and operating requirements. Until now, patients with embedded or worn wireless biosensors had difficulty traveling internationally. Frequency and operating regulations differ from nation to nation, and the results of transmitting and receiving wireless signals on a prohibited spectrum range from irritation to fatal consequences for the person using the biosensor. Bio-Nano Sensium Technologies is a joint venture between Advance Nanotech, Inc. and Toumaz Technology Ltd., a UK-based developer of advanced RF, analog and mixed signal semiconductors.

"Bio-Nano Sensium Technologies is advancing science, and ensuring the comfort of patients of chronic illness," said Stephanie Interbartolo, SVP of Business Development of Advance Nanotech. "The company has removed a significant barrier to the widespread use of wireless devices for medical applications, bringing down costs of ownership and facilitating practical new treatments."

This latest patent is the first filed by Bio-Nano Sensium in the past year in its own name with a plan to file additional patents by year's end. Bio-Nano Sensium also has exclusive access to Toumaz Technology's patent portfolio in the bio-nano field. The increasing number of patents reflects the company's rapid progress in its scientific discovery process toward offering the market's most advanced wireless biosensors.

"The technology we are patenting is a huge step forward in our goal of developing biosensor platforms that have real and immediate impact in the treatment of chronic conditions," said Keith Errey, CEO of Toumaz Technology. "We have worked diligently over the past four years to develop a patented, low-power platform technology to leverage for this kind of important commercial application. It is gratifying to see us come a large step closer to realizing this goal."

About Toumaz Technology Ltd.

Toumaz Technology Limited is a developer of advanced RF, analogue and mixed signal semiconductors. The focus of the business is low power devices based on the company's proprietary AMx(tm) (Advanced Mixed Signal) technology which addresses the needs of lower power consumption for mobile and wirelessly connected systems.

About Advance Nanotech, Inc.

Advance Nanotech Inc. is dedicated to ensuring nanotechnology discoveries reach maximum market potential through successful commercialization. Advance is the trusted guide to commercial success for nanotech entrepreneurs spanning the globe, partnering with leading universities to provide scientists and researchers with mission critical infrastructure support to transform their discoveries to marketable solutions. The organization provides a range of services and support including financing, leadership assets and counsel on intellectual property, licensing and regulatory issues. With a portfolio of nearly 20 companies developing technologies which offer potentially breakthrough nanotechnology discoveries in the electronics, biopharma and materials sectors, Advance's goal is to transform the potential for nanotechnology discoveries into innovative products that further evolve existing industries and enable new markets.

This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements.

Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech 's dependence on third parties and partners; and those risks described Advance Nanotech 's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements.

Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.